Category: 380843-75-4

On February 29, 2020, Shinoda, Kazunobu; Morita, Shinya; Tamaki, Satoshi; Takahashi, Ryohei; Kitaoka, Sotaro; Asanuma, Hiroshi; Yoshida, Tadashi; Okayama, Mikio; Kasahara, Hidenori; Okamoto, Shinichiro; Oya, Mototsugu published an article.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Successful Treatment of End-stage Renal Disease in a Patient With Chronic Myeloid Leukemia by Kidney Transplantation and Tyrosine Kinase Inhibitors: A Case Report. And the article contained the following:

Consensus regarding kidney transplantation feasibility in patients with chronic myeloid leukemia (CML) well controlled by tyrosine kinase inhibitors has not yet been achieved. Here, we report a patient with CML well controlled by tyrosine kinase inhibitors who developed end-stage renal disease during treatment and underwent kidney transplantation. CML activity has been carefully and successfully controlled for 4 years post-transplant. Very cautious dose adjustment and temporary cessation of nilotinib were required because kidney function fluctuated in reference to the doses of nilotinib. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to tki renal disease chronic myeloid leukemia kidney transplantation human, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Name: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On May 31, 2021, Valencia, Hugo J.; de Aguiar, Mara C. A. M.; Costa, Mariana A.; Mendonca, Diogo C.; Reis, Erik V.; Arias, Nidia E. C.; Drumond, Betania P.; Bonjardim, Claudio A. published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Evaluation of kinase inhibitors as potential therapeutics for flavivirus infections. And the article contained the following:

The recent introduction of Zika virus (ZIKV), the recurrence of dengue virus (DENV), and the lethality of yellow fever virus (YFV) have had a significant impact on Brazilian society and public health. Here, we targeted two cellular kinases implicated in cell proliferation and cancer that are also important for viral replication: mitogen-activated protein kinase kinase (MEK) and Src. We used two MEK inhibitors – trametinib and selumetinib – and two Src inhibitors – saracatinib and bosutinib – to inhibit ZIKV, DENV, and YFV replication in cell culture. The cytotoxicity of the four inhibitors was determined by the observation of abnormal morphol. and quantification of adherent cells by crystal violet staining. The antiviral activity of these drugs was assessed based on the reduction of plaque-forming units in cell culture as evidence of the inhibition of the replication of the selected flaviviruses. All four inhibitors showed antiviral activity, but among them, trametinib was the safest and most efficacious against all of the viruses, inhibiting the replication of ZIKV and YFV by 1000-fold, and DENV2/3 by nearly 100-fold. This pan-antiviral effect shows that trametinib could be repurposed for the treatment of flaviviral infections. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to mek src kinase inhibitor therapeutics flavivirus infection, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2020, Hochhaus, Andreas; Gambacorti-Passerini, Carlo; Abboud, Camille; Gjertsen, Bjoern Tore; Bruemmendorf, Tim H.; Smith, B. Douglas; Ernst, Thomas; Giraldo-Castellano, Pilar; Olsson-Stroemberg, Ulla; Saussele, Susanne; Bardy-Bouxin, Nathalie; Viqueira, Andrea; Leip, Eric; Russell-Smith, T. Alexander; Leone, Jocelyn; Rosti, Gianantonio; Watts, Justin; Giles, Francis J.; on behalf of the BYOND Study Investigators published an article.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study. And the article contained the following:

Bosutinib is approved for newly diagnosed Philadelphia chromosome-pos. (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382), 163 CML patients resistant/intolerant to prior TKIs (n = 156 Ph+ CP CML, n = 4 Ph+ AP CML, n = 3 Ph-neg./BCR-ABL1+ CML) received bosutinib 500 mg once daily (starting dose). As of ≥1 yr after last enrolled patient (median treatment duration 23.7 mo), 56.4% of Ph+ CP CML patients remained on bosutinib. Primary endpoint of cumulative confirmed major cytogenetic response (MCyR) rate by 1 yr was 75.8% in Ph+ CP CML patients after one or two prior TKIs and 62.2% after three prior TKIs. Cumulative complete cytogenetic response (CCyR) and major mol. response (MMR) rates by 1 yr were 80.6% and 70.5%, resp., in Ph+ CP CML patients overall. No patient progressed to AP/BP on treatment. Across all patients, the most common treatment-emergent adverse events were diarrhea (87.7%), nausea (39.9%), and vomiting (32.5%). The majority of patients had confirmed MCyR by 1 yr and MMR by 1 yr, further supporting bosutinib use for Ph+ CP CML patients resistant/intolerant to prior TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to human bosutinib chronic myeloid leukemia pretreatment, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Abbas, Hosna Hasan; Al Mosawy, Karrar Kadim published an article in 2020, the title of the article was Overview of chronic myeloid leukemia patients in the holy city of Karbala.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by presence of Philadelphia chromosome. Over time CML treatment has change dramatically; especially when Tyrosine Kinase Inhibitor (TKI) introduced, which significantly increase survival and improve quality of life for all patients especially when its associated with good drug adherence and sequential response monitoring to TKI. To study the characteristics of CML patient’s in the Holy City of Karbala and the outcome of Tyrosine Kinase Inhibitor in control of their disease. The present descriptive study included 56 patients, conducted in Al Imam Al Hussein Hematol./Oncol. center at the Holy city of Karbala in Iraq from June 2017 – June 2018. Data from patients with CML were collected and critically analyzed for the demog. data, type of treatment they used and their compliance to drug. The median age was 46 years; male-to-female ratio was 1.24:1. 96.4% patients were diagnosed in chronic phase of their disease. Major mol. response achieved in 79% (27/34) of patients on Gleevec. 37.5% patients were switch to Tasigna after Imatinib resistant or intolerance, 52% of them achieved major mol. response. Drug adherence found in 68% (38/56) patients. CML slightly male predominance, diagnosed at age younger than that report in the United States and Europe, response to TKI nearly similar to that report in international study. Drug adherence and sequential monitoring of patients can improve therapeutic effect of TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to chronic myeloid leukemia patients holy city karbala, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2022, Shimazu, Yutaka; Murata, Makoto; Kondo, Takeshi; Minami, Yosuke; Tachibana, Takayoshi; Doki, Noriko; Uchida, Naoyuki; Ozawa, Yukiyasu; Yano, Shingo; Fukuda, Takahiro; Kato, Jun; Ara, Takahide; Eto, Testuya; Ishikawa, Jun; Nakamae, Hirohisa; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko; the working group of the Japan Society for Transplantation and Cellular Therapy published an article.Product Details of 380843-75-4 The title of the article was The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. And the article contained the following:

The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16-75) who underwent their first allo-SCT between Jan. 2001 and Dec. 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-yr OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), resp. (p = 0.017). Multivariate anal. confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup anal. showed poor prognoses for patients who could not obtain a mol. response before allo-SCT and patients with pos. T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4

The Article related to tyrosine kinase inhibitor allogenic stem cell transplantation myeloid leukemia, allogeneic stem cell transplantation, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Product Details of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Chiwata, Masahiko; Itonaga, Hidehiro; Sato, Shinya; Hashimoto, Miki; Fujioka, Machiko; Kasai, Sachie; Sakamoto, Hikaru; Toriyama, Eo; Nakashima, Jun; Kamijo, Rena; Kitanosono, Hideaki; Kobayashi, Yuji; Horai, Makiko; Taguchi, Masataka; Matsuo, Masatoshi; Makiyama, Junya; Takasaki, Yumi; Matsuo, Emi; Horio, Kensuke; Ando, Koji; Sawayama, Yasushi; Taguchi, Jun; Kawaguchi, Yasuhisa; Tsushima, Hideki; Imanishi, Daisuke; Imaizumi, Yoshitaka; Yoshida, Shinichiro; Jo, Tatsuro; Nonaka, Hiroaki; Moriuchi, Yukiyoshi; Nagai, Kazuhiro; Yokota, Ken-ichi; Hata, Tomoko; Miyazaki, Yasushi published an article in 2021, the title of the article was Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: a report from the Nagasaki CML study group.Category: piperazines And the article contains the following content:

The standard treatment for chronic myeloid leukemia (CML) is the continuous use of tyrosine kinase inhibitors (TKIs), which results in a favorable prognosis for the majority of patients. Recent studies have identified cardiovascular diseases (CVDs) as late adverse events (AEs) related to TKIs. In this study, we evaluated the long-term efficacy and AEs of TKIs, focusing on CVDs. We performed a retrospective survey of CML patients (diagnosed from 2001 to 2016) treated with TKIs in Nagasaki Prefecture. Clin. data were obtained from their medical records. We analyzed the survival, estimated cumulative incidence of CVDs, and risk factors for CVD among CML patients treated with TKIs. The overall survival rate of 264 CML patients treated with TKIs (median age 58 years old) was 89.6% [95% confidence interval (CI), 84.9-92.9%], and 80.5% (95% CI, 73.4-85.9%) at 5 and 10 years after the CML diagnosis, resp. CVD events occurred in 26 patients (9.8%, median age 67.5 years old) with a median 65.5 mo of TKI treatment. The cumulative incidences at 2 and 5 years was 2.4% (95% CI, 1.0-4.8%) and 5.2% (95% CI, 2.8-8.6%), resp. Hypertension and a high SCORE chart risk at the diagnosis of CML were associated with CVD events during TKI treatment. TKI treatment contributed to the long-term survival of CML patients in Nagasaki Prefecture in a “real-world” setting, but the incidence of CVDs seemed to be increased in these patients. A proper approach to managing risk factors for CVD is warranted to reduce CVD events during TKI treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to cardiovascular adverse event tki treatment efficacy chronic myeloid leukemia, adverse event, cardiovascular disease, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Yue, Xiaomeng; Hincapie, Ana L.; Li, Yuxiang; Guo, Jeff J. published an article in 2022, the title of the article was Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.Computed Properties of 380843-75-4 And the article contains the following content:

To evaluate the cost-effectiveness of ponatinib compared with second-line TKIs in the treatment of adult patients with CML who failed, or were intolerant to, first-line TKIs. A Markov state transition model was conducted. Model transition, adverse-effect probabilities, utility data and medical costs were obtained from clin. trials and literature. Measurements included medications, follow-ups, adverse events, allogeneic stem cell transplantation and quality-adjusted life years (QALYs). Univariable and Bayesian multivariable probabilistic sensitivity analyses were conducted using Monte Carlo simulations. Dasatinib resulted in an ICER of $79,086/QALY compared to nilotinib. Ponatinib yielded an ICER of $176,278/QALY and $141,563/QALY compared to dasatinib and nilotinib, resp. Dasatinib was the optimal treatment at a $100,000/QALY threshold. The probability (36%-40%) for ponatinib or dasatinib optimal treatment was associated with thresholds of $160,000-$180,000/QALY. Dasatinib and ponatinib can be considered cost-effective options and provide clin. benefits compared to other second-line TKIs for CML in the US. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to ponatinib dasatinib anticancer agent economic evaluation chronic myeloid leukemia, treatment outcome, bosutinib, dasatinib, nilotinib, stem cell transplant, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2022, Nakajima, Rui; Matsuo, Takuji; Sumiyoshi, Ritsu; Saito, Sumiko; Yamamoto, Tadashi; Matsumoto, Kensuke; Akiyama, Nobu; Ooi, Jun; Ota, Yasunori; Shirafuji, Naoki; Tashiro, Haruko published an article.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib. And the article contained the following:

FIrst report of an extramedullary blast crisis in the lymph nodes of a chronic myeloid leukemia (CML) patient on bosutinib. A 78-yr-old man was diagnosed with chronic phase (CP) CML in March 2015 and was treated with dasatinib 100 mg once daily as a first-line therapy. An excisional lymph node biopsy revealed the proliferation of blast cells with a starry-sky appearance. Bone marrow anal. did not indicate an increase in abnormal cells, and FISH anal. showed an absence of BCR-ABL1 fusion genes. From these findings, the patient was diagnosed with extramedullary B-lymphoid blast crisis that occurred in CP CML while under MMR. This case demonstrates the need to be mindful of the possibility of extramedullary disease even in patients having achieved MMR following TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib antitumor chronic myeloid leukemia extramedullary blast crisis, cml, bosutinib, extramedullary, ponatinib, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Zhang, Lishun; Yang, Zichao; Sang, Huiting; Jiang, Ying; Zhou, Mingfeng; Huang, Chuan; Huang, Chunhui; Wu, Xiaoyun; Zhang, Tingting; Zhang, Xingmei; Wan, Shanhe; Zhang, Jiajie published an article in 2021, the title of the article was Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.Recommanded Product: 380843-75-4 And the article contains the following content:

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention. Herein, a new series of imidazo[4,5-c]pyridin-2-one derivatives were designed and synthesized as SFK inhibitors. Compounds , , , exhibited potential Src and Fyn kinase inhibition in the submicromolar range, of which were next tested for their antiproliferative potency on four GBM cell lines. Compound showed effective activity against U87, U251, T98G, and U87-EGFRvIII GBM cell lines, comparable to that of lead compound PP2. Mol. dynamics (MDs) simulation revealed the possible binding patterns of the most active compound in ATP binding site of SFKs. ADME prediction suggested that accord with the criteria of CNS drugs. These results led us to identify a novel SFK inhibitor as candidate for GBM treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4

The Article related to dasatinib anticancer agent glioblastoma, glioblastoma, src family kinase, imidazo[4,5-c]pyridin-2-one, kinase inhibitor, molecular simulation, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Claudiani, Simone; Janssen, Jeroen J. W. M.; Byrne, Jenny; Smith, Graeme; Blijlevens, Nicole; Raghavan, Manoj; Smith, Matthew; Clark, Richard E.; Mclain-Smith, Susan; Carter, Angela M.; Milojkovic, Dragana; Apperley, Jane F. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. And the article contained the following:

To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 mo. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major mol. response rates in CP patients were 67% and 55%, resp. After a median follow-up of 21.5 mo, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, resp. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%). Bosutinib used in routine clin. practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib anticancer agent chronic myeloid leukemia, bosutinib, chronic myeloid leukemia, retrospective studies, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics